NASDAQ:ARAVAravive Stock Price, Forecast & News

$12.72

-0.09 (-0.70 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$12.58

Now: $12.72▼

$13.19

50-Day Range

$7.45

MA: $12.06▼

$14.30

52-Week Range

$3.34

Now: $12.72▼

$15.62

Volume104,381 shs

Average Volume166,898 shs

Market Capitalization$202.87 million

P/E RatioN/A

Dividend YieldN/A

Beta3.52

Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Aravive has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $26.00, Aravive has a potential upside of 104.4% from its current price of $12.72.
Amount of Analyst Coverage
Aravive has only been the subject of 1 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Aravive has received 82 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Aravive has received 79 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Aravive has received 50.93% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote “Outperform” if you believe ARAV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Aravive does not currently pay a dividend.
Dividend Growth
Aravive does not have a long track record of dividend growth.

2.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aravive insiders have not sold or bought any company stock.
Percentage Held by Insiders
39.80% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
41.74% of the stock of Aravive is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Aravive are expected to decrease in the coming year, from ($1.91) to ($1.93) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aravive is -6.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aravive is -6.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aravive has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.60 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ARAV

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.aravive.com

Phone936-355-1910

Debt

Debt-to-Equity Ratio0.12

Current Ratio12.36

Quick Ratio12.36

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$4.75 million

Price / Sales42.71

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.71 per share

Price / Book2.70

Profitability

EPS (Most Recent Fiscal Year)($1.57)

Net Income$-18,220,000.00

Net MarginsN/A

Return on Equity-37.54%

Return on Assets-30.30%

Miscellaneous

Employees14

Outstanding Shares15,949,000

Market Cap$202.87 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive ARAV News and Ratings via Email

Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter.

Aravive (NASDAQ:ARAV) Frequently Asked Questions

How has Aravive's stock been impacted by COVID-19 (Coronavirus)?

Aravive's stock was trading at $4.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARAV shares have increased by 154.9% and is now trading at $12.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Aravive?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive.

When is Aravive's next earnings date?

Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Aravive.

How were Aravive's earnings last quarter?

Aravive Inc (NASDAQ:ARAV) announced its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.36. View Aravive's earnings history.

What price target have analysts set for ARAV?

5 brokers have issued twelve-month price objectives for Aravive's shares. Their forecasts range from $15.00 to $31.00. On average, they expect Aravive's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 104.4% from the stock's current price. View analysts' price targets for Aravive.

Has Aravive been receiving favorable news coverage?

Media coverage about ARAV stock has been trending extremely positive this week, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Aravive earned a news impact score of 5.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAravive.

Are investors shorting Aravive?

Aravive saw a decrease in short interest in May. As of May 15th, there was short interest totaling 604,900 shares, a decrease of 9.8% from the April 30th total of 670,800 shares. Based on an average daily trading volume, of 173,500 shares, the days-to-cover ratio is currently 3.5 days. Approximately 7.1% of the shares of the stock are short sold. View Aravive's Current Options Chain.

Who are some of Aravive's key competitors?

Some companies that are related to Aravive include Cue Biopharma (CUE), Gossamer Bio (GOSS), Omeros (OMER), Arcturus Therapeutics (ARCT), Kura Oncology (KURA), Collegium Pharmaceutical (COLL), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Molecular Templates (MTEM), Kadmon (KDMN), Eagle Pharmaceuticals (EGRX), Retrophin (RTRX), Kala Pharmaceuticals (KALA), Ardelyx (ARDX) and Provention Bio (PRVB). View all competitors.

What other stocks do shareholders of Aravive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Applied Genetic Technologies (AGTC), Ardelyx (ARDX), Bank of America (BAC), Clovis Oncology (CLVS), Precision BioSciences (DTIL), Galmed Pharmaceuticals (GLMD), Inovio Pharmaceuticals (INO) and Myovant Sciences (MYOV).

Who are Aravive's key executives?

Aravive's management team includes the following people:

Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)
Dr. Jeffrey L. Cleland, Co-Founder (Age 54)
Dr. Joshua Silverman Ph.D., Co-Founder
Mr. Vinay Shah, Chief Financial Officer
Dr. Gail F. McIntyre, Chief Scientific Officer (Age 56)

What is Aravive's stock symbol?

Aravive trades on the NASDAQ under the ticker symbol "ARAV."

Who are Aravive's major shareholders?

Aravive's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.34%), Two Sigma Advisers LP (1.01%), Alpine Global Management LLC (1.03%), Two Sigma Investments LP (0.80%), Geode Capital Management LLC (0.55%) and UBS Group AG (0.53%). Company insiders that own Aravive stock include Jay Shepard, Kevin Haas and Srinivas Akkaraju. View institutional ownership trends for Aravive.

Which major investors are selling Aravive stock?

ARAV stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., Morgan Stanley, and UBS Group AG. View insider buying and selling activity for Aravive.

Which major investors are buying Aravive stock?

ARAV stock was purchased by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Alpine Global Management LLC, Connor Clark & Lunn Investment Management Ltd., Geode Capital Management LLC, Invesco Ltd., Wedbush Securities Inc., Jane Street Group LLC, and Acadian Asset Management LLC. View insider buying and selling activity for Aravive.

How do I buy shares of Aravive?

Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aravive's stock price today?

One share of ARAV stock can currently be purchased for approximately $12.72.

How big of a company is Aravive?

Aravive has a market capitalization of $202.87 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe.

What is Aravive's official website?

The official website for Aravive is www.aravive.com.

How can I contact Aravive?

Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff